Navigation Links
Watson Names Mark Durand Chief Financial Officer
Date:11/16/2007

CORONA, Calif., Nov. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced the appointment of Mark W. Durand, 48, as Senior Vice President and Chief Financial Officer.

Mr. Durand brings to Watson more than 20 years of executive pharmaceutical experience in finance, operations, business development and marketing. As Senior Vice President and Chief Financial Officer for Watson, Mr. Durand will be responsible for all of the Company's financial operations and will play a principal role in Watson's corporate development activities. He will report directly to Paul Bisaro, Watson's President and Chief Executive Officer.

"We are excited to bring someone with Mark's experience to join the executive management team," said Paul Bisaro. "His extensive experience in both the generic and branded pharmaceutical industries and familiarity with our business model will complement the strength we have within our finance and corporate development groups as we continue to position Watson for future growth."

Mr. Durand joins Watson following his position as Chief Financial Officer and Senior Vice President Finance and Business Development for Teva Pharmaceuticals N.A., where he was responsible for all financial functions and business development activities related to Teva's North America operations, including licensing activities. He also played an integral role in the integration of Ivax Pharmaceuticals after it was acquired by Teva. Prior to his tenure at Teva, Mr. Durand held a number of positions of growing responsibility in the areas of finance, business development and marketing at Bristol-Myers Squibb. His financial roles there included Vice President US Pharmaceutical Group and Vice President Finance and Business Development for Bristol's Worldwide Consumer Medicines and Specialty Pharmaceuticals Division.

Mr. Durand received a Bachelor of Science degree in Zoology from Duke University, a Master of Science degree in Biological Sciences from Dartmouth College and a Master of Business Administration from the University of Chicago.

Forward-Looking Statement

Any statements contained in this press release that refer to future events or other non-historical facts are forward-looking statements that reflect Watson's current perspective of existing trends and information as of the date of this release. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements. Actual results may differ materially from Watson's current expectations depending upon a number of factors affecting Watson's business. These factors include, among others, risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's Annual Report on Form 10-K for the year ended December 31, 2006.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020214/WATSONLOGO)


'/>"/>
SOURCE Watson Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
2. Watson Wyatt Identifies Major Benefit Trends During Open Enrollment Season
3. Texas Affiliates of Susan G. Komen for the Cure, Sen. Kirk Watson, Rep. Patrick Rose, Singer Kelly Willis, Breast Cancer Survivors and Activists Rally for Passage of Proposition 15
4. Watson Files FDA Application for Generic YAZ(R)
5. ResMed Names Kieran Gallahue as Chief Executive Officer, Effective January 1, 2008.
6. Mediware Names Thomas K. Mann Chief Executive Officer
7. Cleveland-based Health Care Tech Company Within3 Names New CEO
8. STERIS Corporation Board of Directors Names Walter M. Rosebrough Jr. President and Chief Executive Officer
9. Patient Safety Authority Board of Directors Names Infection Advisory Panel
10. Hooper Holmes Names Chris Behling President of Health & Wellness Division
11. MDMA Names New Director of Federal Affairs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... ... The Radiology Business Management Association (RBMA) has named the nine winners ... year, are among the most prestigious in radiology marketing because a panel of radiology ... recognize achievements in both large budget (over $5,000) and small budget (under $5,000) campaigns. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Texas Physical Therapy Specialists (TexPTS) is pleased ... Huebner Road. The clinic is the group’s 7th location in San Antonio and 23rd ... PT, will provide care from the clinic, which opened March 22, 2017. ...
(Date:3/24/2017)... ... March 24, 2017 , ... Mlynarek ... services to families and business owners across eastern Michigan, is connecting with the ... struggling with financial difficulties. , The Oxford/Orion FISH Food Pantry works to ensure ...
(Date:3/24/2017)... ... March 24, 2017 , ... In just two days, Aqua ... micro-veggies garden on Kickstarter . Surpassing the $100,000 milestone so quickly,10-times the ... consumers (and counting) already backing the campaign. , “We are very grateful ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... ... Assili, announce that they are now offering treatments for sleep apnea and TMJ ... dental offices. Sleep apnea , specifically the obstructive type, is increasingly being ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... , March 24, 2017 ... the industry including definitions, classifications, applications and industry chain ... international market including development history, competitive landscape analysis, and ... ... industry spread across 105 pages providing 10 company profiles ...
(Date:3/24/2017)... Research and Markets has announced the addition of the ... to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
(Date:3/24/2017)... -- Eli Lilly and Company (NYSE: LLY ... in its U.S. operations in 2017. The company,s ... research laboratories, manufacturing sites, and general and administrative ... for Lilly products, as well as its robust ... pain, diabetes and other unmet medical needs.  ...
Breaking Medicine Technology: